Publications by authors named "N Chiarelli"

: Dominant mutations in are known to cause vascular Ehlers-Danlos syndrome (vEDS) by impairing extracellular matrix (ECM) homeostasis. This disruption leads to the fragility of soft connective tissues and a significantly increased risk of life-threatening arterial and organ ruptures. Currently, treatments for vEDS are primarily symptomatic, largely due to a limited understanding of its underlying pathobiology and molecular mechanisms.

View Article and Find Full Text PDF

Diagnosing hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD), common overlapping multisystemic conditions featuring symptomatic joint hypermobility, is challenging due to lack of established causes and diagnostic tools. Currently, the 2017 diagnostic criteria for hEDS are used, with non-qualifying cases classified as HSD, although the distinction remains debated. We previously showed extracellular matrix (ECM) disorganization in both hEDS and HSD dermal fibroblasts involving fibronectin (FN), type I collagen (COLLI), and tenascin (TN), with matrix metalloproteinase-generated fragments in conditioned media.

View Article and Find Full Text PDF
Article Synopsis
  • - Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic disorder caused by mutations in the gene for type III collagen, leading to fragile blood vessels and serious complications like aneurysms or ruptures, particularly affecting medium-sized arteries.
  • - Previously, vEDS was associated with a high mortality rate and an average life expectancy of around 50 years, but recent advancements in medical awareness and treatment have improved patient outcomes significantly.
  • - Current treatments, particularly the use of celiprolol, a specific heart medication, have shown promise in reducing vascular incidents in vEDS patients; however, more research is needed to fully understand its benefits, and other potential therapeutic avenues are being explored for future treatment. *
View Article and Find Full Text PDF

Vascular Ehlers-Danlos syndrome (vEDS) is a severe connective tissue disorder caused by dominant mutations in the COL3A1 gene encoding type III collagen (COLLIII). COLLIII is primarily found in blood vessels and hollow organs, and its deficiency leads to soft connective tissues fragility, resulting in life-threatening arterial and organ ruptures. There are no current targeted therapies available.

View Article and Find Full Text PDF

The most common conditions with symptomatic joint hypermobility are hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). Diagnosing these overlapping connective tissue disorders remains challenging due to the lack of established causes and reliable diagnostic tests. hEDS is diagnosed applying the 2017 diagnostic criteria, and patients with symptomatic joint hypermobility but not fulfilling these criteria are labeled as HSD, which is not officially recognized by all healthcare systems.

View Article and Find Full Text PDF